Pharming Group N.V. (ADR)
General ticker "PHAR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.0B (TTM average)
Pharming Group N.V. (ADR) does not follow the US Stock Market performance with the rate: -21.7%.
Estimated limits based on current volatility of 1.4%: low 11.26$, high 11.57$
Factors to consider:
- Total employees count: 229 as of 2020
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.46$, 20.06$]
- 2026-12-31 to 2027-12-31 estimated range: [10.44$, 18.69$]
Financial Metrics affecting the PHAR estimates:
- Positive: with PPE of 1746.4 at the end of fiscal year the price was neutral
- Positive: 2.37 < Operating cash flow per share per price, % of 4.39
- Positive: 4.60 < Operating profit margin, % of 5.55
- Positive: -0.55 < Return on assets ratio (scaled to [-100,100]) of 0.57
- Positive: 49.86 < Shareholder equity ratio, % of 55.42 <= 58.56
- Negative: -3.92 < Inventory ratio change, % of -1.55
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PHAR quotes
Long-term PHAR plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $297.20MM | $376.13MM |
| Operating Expenses | $300.87MM | $355.25MM |
| Operating Income | $-3.67MM | $20.88MM |
| Non-Operating Income | $-4.83MM | $-8.03MM |
| Interest Expense | $9.05MM | $10.72MM |
| R&D Expense | $83.15MM | $100.37MM |
| Income(Loss) | $-8.49MM | $12.85MM |
| Taxes | $0.00MM | $10.31MM |
| Net Income(Loss)* | $-11.84MM | $2.85MM |
| Stockholders Equity | $228.91MM | $277.02MM |
| Inventory | $57.70MM | $64.88MM |
| Assets | $414.18MM | $499.81MM |
| Operating Cash Flow | $-1.79MM | $54.71MM |
| Capital expenditure | $0.80MM | $0.76MM |
| Investing Cash Flow | $31.62MM | $26.25MM |
| Financing Cash Flow | $-34.41MM | $1.50MM |
| Earnings Per Share** | $-0.17 | $0.04 |
| Ordinary share to ADR | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.